Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.47 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27561514 | 0.82 | MRGPRX1 (0.46) | MRGPRX1PGAM1KCNK3KCNK9PARP14 | |
| SCHEMBL10570368 | 0.80 | GAA (0.41) | ACLY | |
| SCHEMBL10570687 | 0.80 | ALDH1A1 (0.51) | ACLY | |
| SCHEMBL10567331 | 0.79 | PTGES2 (0.56) | ACLY | |
| SCHEMBL25219425 | 0.78 | CYP1A2 (0.56) | MRGPRX1KCNK3KCNK9 | |
| SCHEMBL8867334 | 0.77 | PARP14 (0.47) | MRGPRX1PGAM1PARP14AR | |
| SCHEMBL3556511 | 0.76 | SLC16A3 (0.48) | — | |
| SCHEMBL11871635 | 0.76 | PGAM1 (0.57) | MRGPRX1PGAM1PARP14AR | |
| SCHEMBL12255222 | 0.76 | POLB (0.44) | — | |
| SCHEMBL23014679 | 0.76 | PARP14 (0.46) | PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | MRGPRX1 177/4885PGAM1 4676/4885KCNK3 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.